Answers are grounded in this paper and cite their sources.
The pluripotency regulator Nanog (NANOG, for human protein) has been reported to be overexpressed in cancers and in cancer stem cells (CSCs). We have previously shown that NanogP8, encoded by one of the expressed Nanog pseudogenes, is the predominant transcript expressed in several cancers including prostate cancer (PCa). We have also demonstrated that NanogP8 is functionally important in tumorigenesis as its loss impairs tumor regeneration and growth while inducible expression of NanogP8 is sufficient to reprogram androgen-dependent PCa to an androgen-independent and castration-resistant state. In the current study, we combined RT-PCR, subcloning and sequencing to systematically analyze the open reading frame sequences of Nanog and NanogP8 mRNA transcripts in treatment-naïve clinical human PCa (HPCa) specimens. Our results revealed that HPCa did not express the ES cell-specific Nanog1 mRNA but primarily expressed NanogP8 together with several other Nanog pseudogenes including NanogP7 and NanogP6. Interestingly, most HPCa specimens contained multiple isoforms of NanogP8 transcripts, and we identified novel missense mutations in the NanogP8 transcripts that could lead to amino acid changes. Experiments with recombinant proteins, site-directed mutagenesis and Western blotting revealed several mutations that conferred the NanogP8 variant proteins, including NanogP8L61P, NanogP8D64Y, and NanogP8N130S, with unique biochemical properties. Moreover, some mutations furnish NanogP8 isoforms with distinct CSC and oncogenic characteristics. Altogether, this study advances our knowledge of the molecular, biochemical and oncogenic properties of Nanog expression and NanogP8 isoforms in PCa.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: